{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:17:08Z","timestamp":1777418228614,"version":"3.51.4"},"reference-count":62,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[1993,4,1]],"date-time":"1993-04-01T00:00:00Z","timestamp":733622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[1993,4]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To review the chemistry, intracellular metabolism, pharmacokinetics, and clinical trials of zalcitabine (2',3'-dideoxycytidine, ddC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>English-language articles and conference proceedings. The indexing terms used were zalcitabine, 2',3'-dideoxycytidine, and ddC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION:<\/jats:title>\n                    <jats:p>In addition to the manufacturer's package insert, available Phase I and Phase I\/II studies were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION:<\/jats:title>\n                    <jats:p>Clinical experience with ddC has been limited to uncontrolled studies and an expanded-access program. Efficacy was evaluated solely on surrogate markers of HIV disease: CD4+ lymphocyte counts and p24 antigen determinations. Clinical endpoints, such as disease progression and survival rates, must be provided to the Food and Drug Administration (FDA) for continued approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>\n                      The FDA has approved use of ddC in combination with zidovudine (ZDV) as therapy of HIV infection for patients with CD4+ lymphocyte counts \u2264300 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      who have experienced significant clinical or immunologic deterioration. Although ddC has the same mechanism of action as other nucleoside analogs, it is more potent on a molar basis. The drug is stable in gastric pH and has good bioavailability (\u223c70\u201390 percent), but it is rapidly cleared from plasma (half life \u223c1\u20133 h). Intracellular concentrations of ddC triphosphate, the active form, are probably related to plasma concentrations, yet may persist in cells longer than the parent drug persists in plasma. When used as primary therapy in patients with CD4+ \u2264300 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      , ddC\/ZDV increased CD4+ lymphocyte counts and reduced plasma p24 antigen concentrations. In comparison to ZDV monotherapy data taken from other studies, ddC\/ZDV appeared to demonstrate a more pronounced and sustained increase in CD4+ cell counts; however, this observation cannot be confirmed until the results of ZDV-controlled comparisons are available. Overall, 17\u201331 percent of the patients receiving the currently recommended initial dosage of ddC experience peripheral neuropathy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In combination with ZDV, ddC appears to augment the CD4+ cell response of ZDV monotherapy in the treatment of HIV infection for ZDV-naive patients, although controlled studies and rigorous statistical analyses are lacking at present. The efficacy of ddC\/ZDV in patients who received prior treatment with ZDV monotherapy is unclear at the present.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/106002809302700416","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T11:24:49Z","timestamp":1484306689000},"page":"480-489","source":"Crossref","is-referenced-by-count":18,"title":["Zalcitabine"],"prefix":"10.1177","volume":"27","author":[{"given":"S. Diane","family":"Goodwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney V.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice M.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1993,4,1]]},"reference":[{"key":"bibr-bibr1-106002809302700416","volume-title":"HIVID (zalcitabine)","year":"1992"},{"key":"bibr-bibr2-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198909143211106"},{"key":"bibr-bibr3-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90178-5"},{"key":"bibr-bibr4-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.20.7096"},{"key":"bibr-bibr5-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1038\/325773a0"},{"key":"bibr-bibr6-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1084\/jem.166.4.1144"},{"key":"bibr-bibr7-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1084\/jem.168.3.1111"},{"key":"bibr-bibr8-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1990.6.691"},{"key":"bibr-bibr9-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1126\/science.2467383"},{"key":"bibr-bibr10-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90414-9"},{"key":"bibr-bibr11-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.7.1559"},{"key":"bibr-bibr12-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)91699-5"},{"key":"bibr-bibr13-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.2.394"},{"key":"bibr-bibr14-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(86)90793-X"},{"key":"bibr-bibr15-106002809302700416","unstructured":"Reichman RC, Lambert JS, Strussenberg J, Dolin R. Decreased dideoxyinosine (ddI) sensitivity of HIV isolates obtained from long term recipients of ddI (abstract). In: VII International Conference on AIDS, Florence, Italy, June 16\u201321, 1991."},{"key":"bibr-bibr16-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1126\/science.1716788"},{"key":"bibr-bibr17-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.153"},{"key":"bibr-bibr18-106002809302700416","volume-title":"AZT and ddC resistance mutations in HIV from a patient treated with both agents (abstract 574)","author":"Fitzgibbon J","year":"1992"},{"key":"bibr-bibr19-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.1.82"},{"key":"bibr-bibr20-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.2.378"},{"key":"bibr-bibr21-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.6.920"},{"key":"bibr-bibr22-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(86)90571-X"},{"key":"bibr-bibr23-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)37768-8"},{"key":"bibr-bibr24-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90116-0"},{"key":"bibr-bibr25-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1250"},{"key":"bibr-bibr26-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90685-X"},{"key":"bibr-bibr27-106002809302700416","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0026-895X(25)09762-7","volume":"34","author":"Hao Z","year":"1988","journal-title":"Mol Pharmacol"},{"key":"bibr-bibr28-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)75738-X"},{"key":"bibr-bibr29-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90413-8"},{"key":"bibr-bibr30-106002809302700416","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0026-895X(25)09422-2","volume":"38","author":"T\u00f6rnevik Y","year":"1990","journal-title":"Mol Pharmacol"},{"key":"bibr-bibr31-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0009-2797(91)90052-9"},{"key":"bibr-bibr32-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)80156-9"},{"key":"bibr-bibr33-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90283-8"},{"key":"bibr-bibr34-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03225.x"},{"key":"bibr-bibr35-106002809302700416","first-page":"28","volume":"3","author":"Gustavson LE","year":"1990","journal-title":"J Acquir Immune Defic Syndr"},{"key":"bibr-bibr36-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)83348-7"},{"key":"bibr-bibr37-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199003000-00008"},{"key":"bibr-bibr38-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315215"},{"key":"bibr-bibr39-106002809302700416","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0090-9556(25)06791-1","volume":"15","author":"Kelly JA","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"bibr-bibr40-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.1.99"},{"key":"bibr-bibr41-106002809302700416","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-3-189"},{"key":"bibr-bibr42-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90415-A"},{"key":"bibr-bibr43-106002809302700416","first-page":"1601","volume":"315","author":"Chaisson RE","year":"1986","journal-title":"N Engl J Med"},{"key":"bibr-bibr44-106002809302700416","volume-title":"A note to physicians","year":"1993"},{"key":"bibr-bibr45-106002809302700416","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-1-13"},{"key":"bibr-bibr46-106002809302700416","volume-title":"Videx (didanosine)","year":"1991"},{"key":"bibr-bibr47-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_5.S570"},{"key":"bibr-bibr48-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880121012"},{"key":"bibr-bibr49-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-199109000-00004"},{"key":"bibr-bibr50-106002809302700416","unstructured":"Steinberg JP, Gunthel CJ, White RL, Morris AM, and the AIDS Research Consortium of Atlanta (ARCA). Outcomes and toxicities on 2',3'-dideoxyinosine (ddI) in the expanded access program (abstract 707). Program and abstracts of the 31st Interscience Conference on Antibiotics and Chemotherapy. Washington. DC: American Society for Microbiology, Sept 29-Oct. 2. 1991: 217."},{"key":"bibr-bibr51-106002809302700416","first-page":"459","volume":"84","author":"Schwartz MS","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"bibr-bibr52-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(89)70332-7"},{"key":"bibr-bibr53-106002809302700416","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-2-133"},{"key":"bibr-bibr54-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_5.S513"},{"key":"bibr-bibr55-106002809302700416","first-page":"538","volume":"4","author":"LaLacheur SF","year":"1991","journal-title":"J Acquir Immune Defic Syndr"},{"key":"bibr-bibr56-106002809302700416","unstructured":"Cardinale VA, ed. Drug topics red book update. Oradell, NJ: Medical Economics, August 1992: 16."},{"key":"bibr-bibr57-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199208273270901"},{"key":"bibr-bibr58-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.2.352"},{"key":"bibr-bibr59-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6768.73"},{"key":"bibr-bibr60-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199208000-00009"},{"key":"bibr-bibr61-106002809302700416","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.1.21"},{"key":"bibr-bibr62-106002809302700416","first-page":"1080","volume":"5","author":"Ascher DP","year":"1992","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809302700416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809302700416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:45Z","timestamp":1777374405000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/106002809302700416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,4]]}},"alternative-id":["10.1177\/106002809302700416"],"URL":"https:\/\/doi.org\/10.1177\/106002809302700416","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,4]]}}}